Why the elderly appear to be more severely affected by COVID-19: The potential role of immunosenescence and CMV

Seilesh Kadambari1 | Paul Klenerman2 | Andrew J. Pollard1

1Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK
2Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK

Correspondence
Seilesh Kadambari, Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Room 02-46-10, Level 2, Children’s Hospital, Oxford OX3 9DU, UK. Email: seilesh.kadambari@paediatrics.ox.ac.uk

Summary
The significantly higher mortality rates seen in the elderly compared with young children during the coronavirus disease 2019 (Covid-19) pandemic is likely to be driven in part by an impaired immune response in older individuals. Cytomegalovirus (CMV) seroprevalence approaches 80% in the elderly. CMV has been shown to accelerate immune ageing by affecting peripheral blood T cell phenotypes and increasing inflammatory mediated cytokines such as IL-6. The elderly with pre-existing but clinically silent CMV infection may therefore be particularly susceptible to severe Covid-19 disease and succumb to a cytokine storm which may have been promoted by CMV. Here, we evaluate the potential role of CMV in those with severe Covid-19 disease and consider how this relationship can be investigated in current research studies.

KEYWORDS
CMV, COVID-19, immunosenescence

1 INTRODUCTION

The outbreak of coronavirus disease 2019 (Covid-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appears to cause the highest morbidity and mortality in adults aged over 70 years.1,2 One of the earliest and largest epidemiological studies in children with Covid-19 showed that only 112 (5.6%) of 2143 children had severe disease (defined as hypoxia), 13 (0.6%) developed respiratory or multiorgan failure or acute respiratory distress syndrome (ARDS).3 In China, there have been no reports of children succumbing to Covid-19. The reasons why children appear to develop less severe disease than adults is perplexing and likely multifactorial.

A range of environmental factors (greater transmission in cases who travel or in the workplace, increased contact with sick cases, cigarette smokers) and underlying health conditions (hypertension, diabetes and chronic respiratory disease) have been associated with severe Covid-19 disease and death.2 All of these factors are more common in older adults than in children. The host immune response is also likely to play a pivotal role in accelerating disease progression in elderly individuals infected with SARS-CoV-2.

T cells have a crucial role in controlling viral infections. A central process in immunological ageing (also called immunosenescence) is reduction in thymic activity.4,5 Cytomegalovirus (CMV) seroprevalence increases with age and approaches 80% by the age of 70 years in northern Europe.6,7 In the elderly, CMV causes clonal T cell proliferation, reduction in naive T cell diversity which in turn may lead to reduced capacity for immune responses to novel viral infections such as SARS-CoV-2. This article will consider the potential role of CMV in those with severe COVID-19 disease.
As aged T cells die, the thymus replenishes the T cell pool with naïve T cells. However, thymic output is reduced by 99% in 70 year olds compared with newborns. CMV infection drives compensatory memory T cell proliferation which ensures that overall T cell numbers do not decline significantly as we age. Very large CMV specific T cell responses in older people have parallels to the phenomenon of CMV induced T cell memory inflation seen in preclinical models. The accumulation of terminally differentiated memory T cells and reduction in naïve CD8+ T-cells in the elderly due to thymic involution is associated with influenza vaccine failure in older people. A prospective Canadian study of residents aged over 65 years in 32 nursing homes found high T-reg and high CMV reactive CD4+ T cells were predictive of risk of respiratory viral infections. In the OCTO and NONA Immune studies in Scandinavia, CMV seropositivity and the associated CD8 T cell expansions (inverted CD4:CD8 ratio) were linked to excess mortality in later life. Although these findings are not universally consistent, they have been reproduced in other careful large scale epidemiology studies, for example, the EPIC study which associated high levels of CMV-specific IgG with mortality. Although the impact of CMV on the CD8+ T cell compartment can be dramatic, whether CD8+ T cell expansion plays a direct causal role or is a marker for lack of immune control of CMV in such populations is not fully established.

Multiple small cohort studies have attempted to evaluate the impact of CMV on the immunogenicity of influenza vaccines. A study of 54 recipients of an intradermal influenza vaccine showed that CMV seropositivity was linked to reduced immune responses in individuals over the age of 60 years. The reduced effectiveness seen in this study appeared to be mediated by late differentiated CD4 T cells. A separate study in adults of all ages showed that CMV seropositive individuals over the age of 60 years had impaired B cell predictive biomarkers to influenza vaccine response. These data highlight that chronic CMV infections may have impaired humoral antibody responses. In contrast, a study of 731 residents in long term residential facilities showed that CMV serostatus did not influence pre or post influenza vaccination geometric mean antibody titer (GMT). Similarly, Wald and colleagues, showed that CMV serostatus had no impact on H1N1 influenza vaccine antibody responses in elderly individuals. Finally, a study of 348 individuals aged between 50 and 70 years, showed that CMV infection did not impair pneumococcal vaccine responses.

Thus, overall, CMV seropositivity (with high levels of IgG) and the linked changes in bulk T cell populations appear to correlate with disease risk amongst the elderly (Figure 1). Assessment of CMV serologic and cellular immune responses in SARS-CoV-2 infected individuals and in healthy aged matched controls is required to assess whether there is a relationship between CMV infection (including reactivation) and severity of Covid-19 disease. These data may also help us understand the potential effectiveness of any vaccine against SARS-CoV-2 in populations with high CMV seropositivity and thus inform future vaccine implementation.

**Figure 1** The association between Covid-19, CMV and inflammageing which potentially leads to higher rates of Covid-19-related mortality in the elderly and in ethnic minority populations. Inflammageing is a condition characterised by elevated levels of blood inflammatory markers that carries high susceptibility to chronic morbidity, frailty and early death.
Increased concentrations of IL-6 have been seen in CMV infected individuals with poor responses to influenza vaccine. A longitudinal study of CMV DNA in peripheral monocytes in women over the age of 70 showed that CMV viraemic women had significantly higher IL-6 levels (3.06 + 0.58 vs 1.19 ± 0.37 pg/mL, respectively, P < .001) than those without viraemia. Multiple studies have shown significant associations between IL-6 and mortality in older adults. Schmaltz and colleagues showed a significant association between CMV seropositivity, IL-6 and significant morbidity and mortality in elderly women over the age of 70 years old. The SALSA (Sacramento Area Latino Study on Aging) study, of Hispanic people aged over 60 years old in California, showed that high CMV IgG antibody levels were significantly related to mortality and that this was mediated by IL-6. In 21 individuals with severe Covid-19 disease there were increased cytokine levels (IL-6, IL-10 and TNFα), lymphopenia (in CD4+ and CD8+ T cells), and decreased IFNγ expression in CD4+ T cells are associated with severe Covid-19. These findings have been supported in a larger study of 452 patients which showed reduction in the number of T cells in severe cases. Predictors of mortality from a retrospective, multicentre study of 150 confirmed Covid-19 cases in Wuhan, China, included elevated ferritin (mean 1297.6 ng/mL in non-survivors vs 614.0 ng/mL in survivors; P < .001) and IL-6 (P < .0001), suggesting that mortality might be due to virally driven hyperinflammation. A randomised controlled trial showed that dexamethasone reduced mortality rates by a third in those individuals with severe Covid-19 disease who required mechanical ventilation (29.0% vs 40.7%, RR 0.65 [95% CI 0.51-0.82]). Tocilizumab, a recombinant human IL-6 monoclonal antibody, has been used in Covid-19 infected patients on the intensive care unit and prolonged ICU stay in critically ill patients. A placebo-controlled randomised trial showed that ganciclovir/valganciclovir could significantly reduce CMV reactivation in such patients and potentially shorten duration of ICU stay. It is unknown whether severely affected individuals with Covid-19, who develop a cytokine storm, are also infected with CMV or have CMV reactivation. CMV infection/reactivation may trigger the cytokine storm, play a contributory role or be an innocent bystander in individuals with severe Covid-19 disease. It is likely that the majority of Covid-19 infected elderly ethnic minority patients are CMV seropositive at the time of developing disease. In patients with severe COVID-19 disease understanding the role of CMV reactivation on the immune response may help identify novel treatment strategies to limit the potential inflammatory role of CMV.

5 | CONCLUSION

COVID-19 has disproportionately affected the elderly with significantly higher rates of mortality than in children. This observation has been recorded in every country affected by the pandemic. The rate of CMV seroprevalence increases with age. CMV has been shown to affect peripheral T cell phenotypes, increase inflammatory mediated cytokines such as IL-6 and play a role in immune dysregulation as humans age. The role of CMV in those with severe Covid-19 disease merits exploration through collection of CMV IgG, specific immune cells and viral load in observational cohorts of infected individuals. This may be a potential target for therapy in severe Covid-19.
help inform our understanding of the use of immunomodulatory treatments such as monoclonal antibodies and convalescent sera, determine if CMV specific antiviral treatment has a role in the treatment of Covid-19 individuals and potentially has implications for vaccine implementation.

CONFLICT OF INTEREST
The authors have no competing interest.

ORCID
Seilesh Kadambari https://orcid.org/0000-0003-3658-7635

REFERENCES
1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.
2. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061.
3. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. Pediatrics. 2020;145(6):e20200702.
4. Boraschi D, Aguado MT, Duteil C, et al. The gracefully aging immune system. Sci Transl Med. 2013;5:185ps8.
5. Akbar AN, Vukmanovic-Stjepic M, Taams LS, Macallan DC. The dynamic co-evolution of memory and regulatory CD4+ T cells in the periphery. Nat Rev Immunol. 2007;7:231-237.
6. Lachmann R, Loenenbach A, Waterboer T, et al. Cytomegalovirus (CMV) seroprevalence in the adult population of Germany. PLoS One. 2018;13:e0200267.
7. Vyas AJ, Hesketh LM, Pebody RG. The burden of infection with cytomegalovirus in England and Wales: how many women are infected in pregnancy? Epidemol Infect. 2009;137:526-533.
8. Gruber AL, Hudson LL, Sempowski GD. Immunosenescence of ageing. J Pathol. 2007;211:144-156.
9. Klenerman P, Hill A. T cells and viral persistence: lessons from diverse infections. Nat Immunol. 2005;6:873-879.
10. Karrer U, Siero S, Wagner M, et al. Memory inflation: continuous accumulation of antiviral CD8+ T cells over time. J Immunol. 2003;170(4):2022-2029.
11. Goronzy JJ, Fulbright JW, Crowson CS, Poland GA, O’Fallon WM, Weyand CM. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J Virol. 2001;75:12182-12187.
12. Trzonkowski P, Myśliwa J, Szmit E, et al. Association between cytomegalovirus infection, enhanced proinflammatory response and low level of anti-hemagglutinins during the anti-influenza vaccination—An impact of immunosenescence. Vaccine. 2003;21:3826-3836.
13. Johnstone J, Parsons R, Botelho F, et al. Immune biomarkers predictive of respiratory viral infection in elderly nursing home residents. PLoS One. 2014;9:e108481.
14. Wikby A, Johansson B, Olsson J, Löfgren S, Nilsson BO, Ferguson F. Expansions of peripheral blood CD8 T-lymphocyte subpopulations and an association with cytomegalovirus seropositivity in the elderly: the Swedish NONA immune study. Exp Gerontol. 2002;37:445-453.
15. Olsson J, Wikby A, Johansson B, Lofgren S, Nilsson BO, Ferguson FG. Age-related change in peripheral blood T-lymphocyte subpopulations and cytomegalovirus infection in the very old: the Swedish longitudinal OCTO immune study. Mech Ageing Dev. 2001;121:187-201.
16. Krania-Klotsas E, Langenberg C, Sharp SJ, Luben R, Khaw KT, Wareham NJ. Higher immunoglobulin G antibody levels against cytomegalovirus are associated with incident ischemic heart disease in the population-based EPIC-norfolk cohort. J Infect Dis. 2012;206:1897-1903.
17. Klenerman P, Oxenius A. T cell responses to cytomegalovirus. Nat Rev Immunol. 2016;16(6):367-377.
18. Frasca D, Díaz A, Romero M, Landín AM, Blomberg BB. Cytomegalovirus (CMV) seroprevalence decreases B cell responses to the influenza vaccine. Vaccine. 2015;33:1433-1439.
19. Wald A, Selke S, Magaret A, Boechk M. Impact of human cytomegalovirus (CMV) infection on immune response to pandemic 2009 H1N1 influenza vaccine in healthy adults. J Med Virol. 2013;85:1557-1560.
20. Derhovanessian E, Theeten H, Hähnel K, Van Damme P, Cools N, Pawelec G. Cytomegalovirus-associated accumulation of late-differentiated CD4 T-cells correlates with poor humoral response to influenza vaccination. Vaccine. 2013;31:685-690.
21. Den Elzen WPJ, Vossen ACM, Cools HJM, Westendorp RJG, Kroes ACM, Gussekloo J. Cytomegalovirus infection and responsiveness to influenza vaccination in elderly residents of long-term care facilities. Vaccine. 2011;29(29-30):4869-4874.
22. O’Connor D, Trück J, Lazarus R, et al. The effect of chronic cytomegalovirus infection on pneumococcal vaccine responses. J Infect Dis. 2014;209:1635-1641.
23. Li H, Weng P, Najarro K, et al. Chronic CMV infection in older women: longitudinal comparisons of CMV DNA in peripheral monocytes, anti-CMV IgG titers, serum IL-6 levels, and CMV pp65 (NLV)-specific CD8+ T-cell frequencies with twelve year follow-up. Exp Gerontol. 2014;54:84-89.
24. Leng S, Chaves P, Koenig K, Walston J. Serum interleukin-6 and hemoglobin as physiological correlates in the geriatric syndrome of frailty: a pilot study. J Am Geriatr Soc. 2002;50:1268-1271.
25. Walston J, McBurnie MA, Newman A, et al. Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the cardiovascular health study. Arch Intern Med. 2002;162:2333-2341.
26. Fried LP, Xue QL, Cappola AR, et al. Nonlinear multisystem physiological dysregulation associated with frailty in older women: implications for etiology and treatment. J Gerontol Ser A Biol Sci Med Sci. 2009;64A:1049-1057.
27. Schmelz HN, Fried LP, Xue QL, Walston J, Leng SX, Semba RD. Chronic cytomegalovirus infection and inflammation are associated with prevalent frailty in community-dwelling older women. J Am Geriatr Soc. 2005;53:747-754.
28. Roberts ET, Haan MN, Dowd JB, Aiello AE. Cytomegalovirus antibody levels, inflammation, and mortality among elderly latinos over 9 years of follow-up. Am J Epidemiol. 2010;172:363-371.
29. Chen G, Wu D, Guo W, et al. Clinical and immunologic features in severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130:2620-2629.
30. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020.
31. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846-848.
32. Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the experience of clinical immunologists from China. Clin Immunol. 2020;214:108393.
33. Tookey PA, Ades AE, Peckham CS. Cytomegalovirus prevalence in pregnant women: the influence of parity. Arch Dis Child. 1992;67:779-783.
34. Pembrey L, Raynor P, Griffiths P, Chaytor S, Wright J, Hall AJ. Seroprevalence of cytomegalovirus, Epstein Barr virus and varicella zoster virus among pregnant women in Bradford: a cohort study. PLoS One. 2013;8(11):e81881.
35. Gaytant MA, Galama JMD, Semmekrot BA, et al. The incidence of congenital cytomegalovirus infections in The Netherlands. J Med Virol. 2005;76(1):71-75.
36. Staras SAS, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis. 2006;43:1143-1151.
37. Garg S, Kim LWM, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 -- COVID-NET, 14 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:458–464.
38. Osawa R, Singh N. Cytomegalovirus infection in critically ill patients: a systematic review. Crit Care. 2009;13:R68.
39. Limaye AP, Kirby KA, Rubenfeld GD, et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA. 2008;300:2367.
40. Limaye AP, Stapleton RD, Peng L, et al. Effect of ganciclovir on IL-6 levels among cytomegalovirus-seropositive adults with critical illness: a randomized clinical trial. JAMA. 2017;318:731-740.

How to cite this article: Kadambari S, Klenerman P, Pollard AJ. Why the elderly appear to be more severely affected by COVID-19: The potential role of immunosenescence and CMV. Rev Med Virol. 2020;e2144. https://doi.org/10.1002/rmv.2144